Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations
Clinical trial NCT05299125 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05299125
- Sponsor
- Latin American Cooperative Oncology Group
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-24
- Primary completion
- 2026-01-30
- Enrollment
- 54
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.